Top News: Gilead Sciences Inc. (NASDAQ:GILD), Eagle Pharmaceuticals Inc. (NASDAQ:EGRX), Crescent Point Energy Corp. (NYSE:CPG), Delta Air Lines, Inc. (NYSE:DAL), Agenus (NASDAQ:AGEN)

Gilead Sciences Inc. (NASDAQ:GILD) belongs to Healthcare sector. Its net profit margin is 51.70% and weekly performance is -1.13%. On last trading day company shares ended up $113.74. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 1.09%. On July 03, Gilead Sciences Inc. (NASDAQ:GILD) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, approved by the MHLW under the trade name Sovaldi® in March 2015. Harvoni is indicated for the suppression of viremia in patients with genotype 1 chronic hepatitis C virus (HCV) infection with or without compensated cirrhosis, with treatment duration of 12 weeks.

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares increased 6.02% in last trading session and ended the day at $85.26. EGRX Gross Margin is 71.90% and its return on assets is 3.00%. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) quarterly performance is 72.91%. On June 29, Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) announced that it was added to the Russell 2000®Index and thus the broad-market Russell 3000®Index when the indexes reconstituted at market close on June 26, 2015.

On 10 July, Crescent Point Energy Corp. (NYSE:CPG) shares moved down -4.12% and was closed at $18.87. CPG EPS growth in last 5 year was 97.35%. Crescent Point Energy Corp. (NYSE:CPG) year to date (YTD) performance is -14.68%. Crescent Point Energy Corp. (NYSE:CPG) announces that it has filed a preliminary short form base shelf prospectus (the “Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, and a corresponding registration statement with the United States Securities and Exchange Commission under the Multijurisdictional Disclosure System. Filing of the Prospectus is expected to increase Crescent Point’s flexibility in future financings and is normal practice for a company of Crescent Point’s size. It is also expected to assist the Company in expanding the size and scope of its shareholder base.

Delta Air Lines, Inc. (NYSE:DAL) belongs to Services sector. Its net profit margin is 2.90% and weekly performance is 6.15%. On last trading day company shares ended up $42.46. Delta Air Lines, Inc. (NYSE:DAL) distance from 50-day simple moving average (SMA50) is -1.37%. Announced on July 06, that Delta Air Lines, Inc. (NYSE:DAL) is poised to start using Boeing 757s under a tentative agreement for National Basketball Association charters, with almost 50 percent more cabin space than the planes now on those flights. The accord also calls for ferrying as many as 27 of the 30 NBA teams, four more than last season.

Agenus Inc. (NASDAQ:AGEN) shares increased 3.50% in last trading session and ended the day at $9.17. Its return on assets is -64.30%. Agenus Inc. (NASDAQ:AGEN) quarterly performance is 69.19%. Agenus Inc. (NASDAQ:AGEN) entered into an employment agreement with Dr. Robert Stein, pursuant to which Dr. Stein will continue to serve as the Company’s Chief Scientific Officer. The agreement with Dr. Stein has an initial term of one year and is extended for successive terms of one year each unless either party notifies the other at least 120 days prior to the expiration of the original or any extension term. Dr. Stein’s annual base salary will be increased to $400,000, effective July 1, 2015. Dr. Stein’s annual performance bonus target will remain unchanged at 40% of his annual base salary, with the actual amount of such bonus, if any, to be determined by the Board of Directors. Dr. Stein will also be entitled to continue to participate in the benefits and insurance programs generally available to all Company employees.

Leave a Reply

Your email address will not be published. Required fields are marked *